–A Fresenius SE & Co. executive has said his company experienced testing problems similar to those that Fresenius cited as grounds for pulling out of a $4.3 billion deal to buy U.S. generic-drug maker Akorn Inc., Bloomberg reports.
–Mats Henriksson testified on Thursday in Delaware that it took Fresenius two years to address questions raised by the U.S. Food and Drug Administration in 2013 regarding drug-injection testing and test-result storage at a Fresenius plant in India, Bloomberg said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.